Endotoxin removal therapy with Polymyxin B immobilized fiber column: a single center experience from EUPHAS2 registry.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 10 2023
16 10 2023
Historique:
received:
27
03
2023
accepted:
12
10
2023
medline:
23
10
2023
pubmed:
17
10
2023
entrez:
16
10
2023
Statut:
epublish
Résumé
Although the precise clinical indication for initiation of PMX-HA is widely debated in the literature, a proper patient selection and timing of treatment delivery might play a critical role in the clinical course of a specific subphenotype of septic shock (endotoxic shock). In light of this view, since 2019, we have introduced in our clinical practice a diagnostic-therapeutic flowchart to select patients that can benefit the most from the treatment proposed. In addition, we reported in this study our experience of PMX-HA in a cohort of critically ill patients admitted to our intensive care unit (ICU). We analyzed a single centre, retrospective, observational web-based database (extracted from the EUPHAS2 registry) of critically ill patients admitted to the ICU between January 2016 and May 2021 who were affected by endotoxic shock. Patients were divided according to the diagnostic-therapeutic flowchart in two groups: Pre-Flowchart (Pre-F) and Post-Flowchart (Post-F). From January 2016 to May 2021, 61 patients were treated with PMX-HA out of 531 patients diagnosed with septic shock and of these, fifty patients (82%) developed AKI during their ICU stay. The most common source of infection was secondary peritonitis (36%), followed by community-acquired pneumonia (29%). Fifty-five (90%) out of 61 patients received a second PMX-HA treatment, with a statistically significant difference between the two groups (78% of the Pre-F vs. 100% of the Post-F group, p = 0.005). In both groups, between T0 and T120, the Endotoxin Activity Assay (EAA) decreased, while the SOFA score, mean arterial pressure (MAP), and Vasoactive Inotropic Score (VIS) improved with no statistically significant difference. Furthermore, when performing a propensity score matching analysis to compare mortality between the two groups, statistically significant lower ICU and 90-day mortalities were observed in the Post-F group [p = 0.016]. Although in this experienced centre data registry, PMX-HA was associated with organ function recovery, hemodynamic improvement, and current EAA level reduction in critically ill patients with endotoxic shock. Following propensity score-matched analysis, ICU mortality and 90-day mortalities were lower in the diagnostic-therapeutic flowchart group when considering two temporal groups based on strict patient selection criteria and timing to achieve PMX. Further Randomised Control Trials focused on centre selection, adequate training and a flowchart of action when assessing extracorporeal blood purification use should be performed.
Identifiants
pubmed: 37845296
doi: 10.1038/s41598-023-44850-9
pii: 10.1038/s41598-023-44850-9
pmc: PMC10579294
doi:
Substances chimiques
Endotoxins
0
Polymyxin B
J2VZ07J96K
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17600Informations de copyright
© 2023. Springer Nature Limited.
Références
Singer, M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315(8), 801. https://doi.org/10.1001/jama.2016.0287 (2016).
doi: 10.1001/jama.2016.0287
pubmed: 26903338
pmcid: 4968574
Evans, L. et al. Executive summary: Surviving sepsis campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021. Crit. Care Med. 49(11), 1974–1982. https://doi.org/10.1097/CCM.0000000000005357 (2021).
doi: 10.1097/CCM.0000000000005357
pubmed: 34643578
De Rosa, S., Villa, G. & Ronco, C. The golden hour of Polymyxin B hemoperfusion in endotoxic shock: The basis for sequential extracorporeal therapy in sepsis. Artif. Organs https://doi.org/10.1111/aor.13550 (2019).
doi: 10.1111/aor.13550
pubmed: 31386769
pmcid: 7003912
Tariverdian, T., Zarintaj, P., Milan, P. B., et al. Nanoengineered biomaterials for kidney regeneration. In Nanoengineered Biomaterials for Regenerative Medicine, 325–344 (2019). https://doi.org/10.1016/B978-0-12-813355-2.00014-4 .
Shoji, H. Extracorporeal endotoxin removal for the treatment of sepsis: Endotoxin adsorption cartridge (Toraymyxin). Ther. Apher. Dial. 7(1), 108–114. https://doi.org/10.1046/j.1526-0968.2003.00005.x (2003).
doi: 10.1046/j.1526-0968.2003.00005.x
pubmed: 12921125
Holzheimer, R. G. Antibiotic induced endotoxin release and clinical sepsis: A review. J. Chemother. 13(sup4), 159–172. https://doi.org/10.1179/joc.2001.13.Supplement-2.159 (2001).
doi: 10.1179/joc.2001.13.Supplement-2.159
pubmed: 11936361
Cruz, D. N. et al. Early use of Polymyxin B hemoperfusion in abdominal septic shock: The EUPHAS randomized controlled trial. JAMA 301(23), 2445. https://doi.org/10.1001/jama.2009.856 (2009).
doi: 10.1001/jama.2009.856
pubmed: 19531784
Cutuli, S. L. et al. Endotoxin activity trend and multi-organ dysfunction in critically ill patients with septic shock, who received Polymyxin-B hemadsorption: A multicenter, prospective, observational study. Artif. Organs https://doi.org/10.1111/aor.14534 (2023).
doi: 10.1111/aor.14534
pubmed: 37767775
Romaschin, A. D. et al. A rapid assay of endotoxin in whole blood using autologous neutrophil dependent chemiluminescence. J. Immunol. Methods 212(2), 169–185. https://doi.org/10.1016/S0022-1759(98)00003-9 (1998).
doi: 10.1016/S0022-1759(98)00003-9
pubmed: 9672205
Klein, D. J. et al. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: A post hoc analysis of the EUPHRATES trial. Intensive Care Med. 44(12), 2205–2212. https://doi.org/10.1007/s00134-018-5463-7 (2018).
doi: 10.1007/s00134-018-5463-7
pubmed: 30470853
pmcid: 6280819
Fujii, T. et al. Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: A systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 44(2), 167–178. https://doi.org/10.1007/s00134-017-5004-9 (2018).
doi: 10.1007/s00134-017-5004-9
pubmed: 29204670
Shoji, H. & Ferrer, R. Potential survival benefit and early recovery from organ dysfunction with Polymyxin B hemoperfusion: Perspectives from a real-world big data analysis and the supporting mechanisms of action. J. Anesth. Analg. Crit. Care 2, 27 (2022).
doi: 10.1186/s44158-022-00056-5
pubmed: 37386673
pmcid: 9207853
Martin, E. L. et al. Endotoxin removal: How far from the evidence? The EUPHAS 2 project. In Contributions to Nephrology Vol. 167 (eds Ronco, C. et al.) 119–125 (S. Karger AG, 2010). https://doi.org/10.1159/000315926 .
doi: 10.1159/000315926
Cutuli, S. L. et al. Polymyxin-B hemoperfusion in septic patients: Analysis of a multicenter registry. Ann. Intensive Care 6, 77. https://doi.org/10.1186/s13613-016-0178-9 (2016).
doi: 10.1186/s13613-016-0178-9
pubmed: 27502196
pmcid: 4977232
Godinjak, A. G. Predictive value of SAPS II and APACHE II scoring systems for patient outcome in medical intensive care unit. Acta Medica Acad. 45(2), 89–95. https://doi.org/10.5644/ama2006-124.165 (2016).
doi: 10.5644/ama2006-124.165
Vincent, J. L. et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine (see contributors to the project in the appendix). Intensive Care Med. 22(7), 707–710. https://doi.org/10.1007/BF01709751 (1996).
doi: 10.1007/BF01709751
pubmed: 8844239
Belletti, A., Lerose, C. C., Zangrillo, A. & Landoni, G. Vasoactive-inotropic score: Evolution, clinical utility, and pitfalls. J. Cardiothorac. Vasc. Anesth. 35(10), 3067–3077. https://doi.org/10.1053/j.jvca.2020.09.117 (2021).
doi: 10.1053/j.jvca.2020.09.117
pubmed: 33069558
Kellum, J. A. & Lameire, N. Diagnosis, evaluation, and management of acute kidney injury: A KDIGO summary (Part 1). Crit. Care 17(1), 204. https://doi.org/10.1186/cc11454 (2013).
doi: 10.1186/cc11454
pubmed: 23394211
pmcid: 4057151
De Rosa, S., Samoni, S. & Ronco, C. Creatinine-based definitions: From baseline creatinine to serum creatinine adjustment in intensive care. Crit. Care. 20, 69 (2016).
doi: 10.1186/s13054-016-1218-4
pubmed: 26983854
pmcid: 4794949
Marshall, J. C. et al. Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence. Crit. Care 6, 342–348. https://doi.org/10.1186/cc1522 (2002).
doi: 10.1186/cc1522
pubmed: 12225611
pmcid: 125316
De Rosa, S., Zanella, M., Samoni, S. & Ronco, C. Endotoxin removal therapy with Polymyxin B immobilized fiber column as a COVID-19-bedside strategy protocol for endotoxic shock. Front. Nephrol. https://doi.org/10.3389/fneph.2022.847305:6 (2022).
doi: 10.3389/fneph.2022.847305:6
pubmed: 37675016
pmcid: 10479594
R Core Team. R. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; https://www.R-project.org/ (2021).
Fong, C., Ratkovic, M., & Imai, K. CBPS: Covariate Balancing Propensity Score; https://CRAN.R-project.org/package=CBPS (2019).
Greifer, N. WeightIt: Weighting for Covariate Balance in Observational Studies; https://CRAN.R-project.org/package=WeightIt (2020).
Lepper, P. M. et al. Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Med. 28(7), 824–833 (2002).
doi: 10.1007/s00134-002-1330-6
pubmed: 12122518
Matsuda, T. et al. Differences in neutrophil death among beta-lactam antibiotics after in vitro killing of bacteria. Shock 18(1), 69–74 (2002).
doi: 10.1097/00024382-200207000-00013
pubmed: 12095137
Shoji, H., Tani, T., Hanasawa, K. & Kodama, M. Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: Designing and antiendotoxin efficacy in the clinical application. Ther. Apher. 2, 3–12 (1998).
doi: 10.1111/j.1744-9987.1998.tb00066.x
pubmed: 10227782
Srisawat, N. et al. The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients. Crit. Care 22(1), 279 (2018).
doi: 10.1186/s13054-018-2077-y
pubmed: 30367647
pmcid: 6204024
Chang, T. et al. Effects of Polymyxin B hemoperfusion on mortality in patients with severe sepsis and septic shock: A systemic review, meta-analysis update, and disease severity subgroup meta-analysis. Crit. Care Med. 45, e858–e864 (2017).
doi: 10.1097/CCM.0000000000002362
pubmed: 28445237
pmcid: 5515642
Terayama, T. et al. Polymyxin B hemoperfusion for sepsis and septic shock: A systematic review and meta-analysis. Surg. Infect. 18, 225–233 (2017).
doi: 10.1089/sur.2016.168
Vincent, J. L. et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 23(5), 400–405. https://doi.org/10.1097/01.shk.0000159930.87737.8a (2005).
doi: 10.1097/01.shk.0000159930.87737.8a
pubmed: 15834304
Cruz, D. et al. Effectiveness of Polymyxin B-immobilized fiber column in sepsis: A systematic review. Crit. Care. 11, R47. https://doi.org/10.1186/cc5780 (2007).
doi: 10.1186/cc5780
pubmed: 17448226
pmcid: 2206475
Payen, D. M. et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: A multicenter randomized control trial. Intensive Care Med. 41, 975–984 (2015).
doi: 10.1007/s00134-015-3751-z
pubmed: 25862039
pmcid: 4477725
Dellinger, R. P. et al. effect of targeted Polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: The EUPHRATES randomized clinical trial. JAMA 320, 1455–1463 (2018).
doi: 10.1001/jama.2018.14618
pubmed: 30304428
pmcid: 6233793
Iba, T. & Klein, D. J. The wind changed direction, and the big river flows from EUPHRATES to TIGRIS. J Intensive Care. 7, 31. https://doi.org/10.1186/s40560-019-0386-0 (2019).
doi: 10.1186/s40560-019-0386-0
pubmed: 31131109
pmcid: 6521478
Spectral Diagnostics (US) Inc. A Prospective, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of PMX Cartridge in Addition to Standard Medical Care for Patients With Endotoxemic Septic Shock, accessed 17 August 2022. clinicaltrials.gov; https://clinicaltrials.gov/ct2/show/NCT03901807 (2022).
Fujimori, K., Tarasawa, K. & Fushimi, K. Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: A nationwide observational study. Ann. Intensive Care. 11, 141. https://doi.org/10.1186/s13613-021-00928-z (2021).
doi: 10.1186/s13613-021-00928-z
pubmed: 34568980
pmcid: 8473472
Payen, D. M. et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: A multicenter randomized control trial. Intensive Care Med. 41(6), 975–984. https://doi.org/10.1007/s00134-015-3751-z (2015).
doi: 10.1007/s00134-015-3751-z
pubmed: 25862039
pmcid: 4477725
Forfori, F. et al. Regional citrate-calcium anticoagulation during polymyxin-B hemoperfusion: A case series. Int. J. Artif. Organs 41(6), 319–324 (2018).
doi: 10.1177/0391398818762360
pubmed: 29577795
pmcid: 6159843
Uchino, S. et al. Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 294, 813–818 (2005).
doi: 10.1001/jama.294.7.813
pubmed: 16106006
Mehta, R. L. et al. Sepsis as a cause and consequence of acute kidney injury: Program to improve care in acute renal disease. Intensive Care Med. 37, 241–248 (2011).
doi: 10.1007/s00134-010-2089-9
pubmed: 21152901
Zeng, X., McMahon, G. M., Brunelli, S. M., Bates, D. W. & Waikar, S. S. Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. Clin. J. Am. Soc. Nephrol. 9(1), 12–20 (2014).
doi: 10.2215/CJN.02730313
pubmed: 24178971
Kellum, J. A., Mehta, R. L., Angus, D. C., Palevsky, P. & Ronco, C. The first international consensus conference on continuous renal replacement therapy. Kidney Int. 62(5), 1855–1863 (2002).
doi: 10.1046/j.1523-1755.2002.00613.x
pubmed: 12371989
Clark, E. et al. High-volume hemofiltration for septic acute kidney injury: A systematic review and meta-analysis. Crit. Care 18(1), R7 (2014).
doi: 10.1186/cc13184
pubmed: 24398168
pmcid: 4057068
Villa, G. et al. Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: Practical applications. Crit. Care 20, 283 (2016).
doi: 10.1186/s13054-016-1456-5
pubmed: 27719676
pmcid: 5056485
Borthwick, E. M. et al. High-volume haemofiltration for sepsis in adults. Cochrane Database Syst. Rev. 1(1), CD008075 (2017).
pubmed: 28141912
Chawla, L. S., Bellomo, R. & Bihorac, A. Acute kidney disease and renal recovery: Consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat. Rev. Nephrol. 13(4), 241–257 (2017).
doi: 10.1038/nrneph.2017.2
pubmed: 28239173
Peerapornratana, S., Priyanka, P. & Wang, S. Sepsis-associated acute kidney disease. Kidney Int. Rep. 5(6), 839–850 (2020).
doi: 10.1016/j.ekir.2020.03.005
pubmed: 32518866
pmcid: 7270721
Flannery, A. H. et al. Sepsis-associated acute kidney disease and long-term kidney outcomes. Kidney Med. 3(4), 507-514.e1 (2021).
doi: 10.1016/j.xkme.2021.02.007
pubmed: 34401718
pmcid: 8350838
De Rosa, S. et al. SIAARTI-SIN joint commission. Extracorporeal blood purification therapies for sepsis-associated acute kidney injury in critically ill patients: expert opinion from the SIAARTI-SIN joint commission. J Nephrol. 36(7), 1731–1742 (2023). https://doi.org/10.1007/s40620-023-01637-5
Zarbock, A., Koyner, J. L., Gomez, H., Pickkers, P., Forni, L. Sepsis-associated acute kidney injury treatment standard. Nephrol .Dial. Transplant. (2023). https://doi.org/10.1093/ndt/gfad142